Compare Invesco DB Agriculture Fund (DBA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Viatris Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.32B), while Viatris Inc trades at $17.45 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 15.2× Invesco DB Agriculture Fund's market cap, and Viatris Inc pays a 2.75% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Viatris Inc for 57 Days on average.
| DBA | VTRS | |
|---|---|---|
Market Cap | $1.32B | $20.03B |
Volume | 771,657 | 14,109,977 |
52-Week High | $29.49 | $18.27 |
52-Week Low | $25.44 | $9.74 |
Typical Hold Time | 24 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong year-to-date performance with 12.4% returns matching the S&P 500. The technical outlook remains bullish with moving averages signaling strength and ADX indicators confirming trend momentum. Recent news highlights agricultural ETF outperformance driven by weather risks, geopolitical tensions, and strong global demand for commodities.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and climate factors, though the 0.85% expense ratio and commodity volatility present risks. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish technical consolidation near all-time highs since 2020.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
